EDIT-B®
Differentiation of Unipolar Depression from Bipolar Disorder
Clinically ValidatedActive
Key Facts
Indication
Differentiation of Unipolar Depression from Bipolar Disorder
Phase
Clinically Validated
Status
Active
Company
About Alcediag
Alcediag is an innovative diagnostics company pioneering the application of RNA editing biomarkers and AI to address critical unmet needs in mental health. Its core technology, the EDITECH® platform, analyzes epigenetic modifications in blood to develop tests like EDIT-B®, which aims to differentiate unipolar from bipolar depression. As a private company, Alcediag is positioned in the high-growth precision psychiatry market, leveraging a strong IP portfolio and KOL network to advance its commercial and diagnostic pipeline.
View full company profile